 Home > Active Ingredient News > Antitumor Therapy > RET inhibitor TPX-0046 in the treatment of tumors, phase I/II SWORD-1 phase study has obtained preliminary clinical data

RET inhibitor TPX-0046 in the treatment of tumors, phase I/II SWORD-1 phase study has obtained preliminary clinical data

 Last Update: 2021-04-17
 Source: Internet
 Author: User

Tags

phase glass needles

popcorn cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Turning Point Therapeutics is a precision oncology company dedicated to the development of next-generation therapies that target the genetic drivers of cancer.

The preliminary data in the phase I dose finding part of the study showed preliminary clinical activity, including objective response and generally well-tolerated safety.

Alexander Drilon, General Manager of Early Drug Development Services at Memorial Sloan Kettering Hospital Cancer Center, said: "In the United States and the European Union, RET-driven cancer affects nearly 10,000 patients each year, and treatment with selective RET inhibitors progresses.

The 21 patients included in the study included 10 cases of non-small cell lung cancer ( NSCLC ) and 11 cases of medullary thyroid carcinoma (MTC).

NSCLC

Among the 5 patients who did not undergo RET TKI, 4 showed tumor regression rates of -42%, -37%, -23%, and -3%.

Original source:

href="" target="_blank" rel="noopener">

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.